Prestige Consumer Healthcare Inc.
PBH NYSE Pharmaceutical Preparations Financials FY2017–FY2026
Revenue
Total sales reported in the income statement.
$1.1B
4.3%
vs prior year
Operating margin
Operating income as a share of revenue.
28.4%
1.2 pts
Net income
Profit after all expenses, interest and tax.
$190M
11.3%
Free cash flow
Cash from operations minus capital spending.
$246M
1.3%
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
8.1%
1.2 pts
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On $3.57 EPS (TTM)
What Prestige Consumer Healthcare Inc. does
No business description yet.
- Legal name
- Prestige Consumer Healthcare Inc.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 14, 2026
- Accession · CIK
- 0001295947-26-000016
0001295947
Revenue and margins
Prestige Consumer Healthcare Inc. had $1.1B of revenue in fiscal 2026, down 4.3% on the year before.
FY17
Revenue $882M
FY18
Revenue $1.0B
FY19
Revenue $976M
FY20
Revenue $963M
FY21
Revenue $943M
FY22
Revenue $1.1B
FY23
Revenue $1.1B
FY24
Revenue $1.1B
FY25
Revenue $1.1B
FY26
Revenue $1.1B
Q2 '24
Revenue $286M
Q3 '24
Revenue $283M
Q4 '24
Revenue $277M
Q1 '25
Revenue $267M
Q2 '25
Revenue $284M
Q3 '25
Revenue $290M
Q4 '25
Revenue $297M
Q1 '26
Revenue $250M
Q2 '26
Revenue $274M
Q3 '26
Revenue $283M
Q4 '26
Revenue $282M
Q1 '27
Revenue $266M
FY17
Gross 56.7%
Operating 23.3%
Net 7.9%
FCF 16.5%
FY18
Gross 55.4%
Operating 20.7%
Net 32.6%
FCF 19.0%
FY19
Gross 56.9%
Operating 6.9%
Net −3.7%
FCF 18.3%
FY20
Gross 57.3%
Operating 30.2%
Net 14.8%
FCF 21.0%
FY21
Gross 58.0%
Operating 31.5%
Net 17.5%
FCF 22.6%
FY22
Gross 57.1%
Operating 30.4%
Net 18.9%
FCF 23.0%
FY23
Gross 55.4%
Operating −2.0%
Net −7.3%
FCF 19.7%
FY24
Gross 55.5%
Operating 30.4%
Net 18.6%
FCF 21.3%
FY25
Gross 55.8%
Operating 29.6%
Net 18.9%
FCF 21.4%
FY26
Gross 54.7%
Operating 28.4%
Net 17.5%
FCF 22.6%
Gross
Operating
Net
FCF
Q2 '24
Gross 55.9%
Operating 30.8%
Net 18.7%
FCF 20.8%
Q3 '24
Gross 55.9%
Operating 30.7%
Net 18.8%
FCF 24.6%
Q4 '24
Gross 54.8%
Operating 29.7%
Net 17.9%
FCF 23.0%
Q1 '25
Gross 54.7%
Operating 27.0%
Net 18.4%
FCF 20.1%
Q2 '25
Gross 55.5%
Operating 29.7%
Net 19.2%
FCF 23.9%
Q3 '25
Gross 55.5%
Operating 31.7%
Net 21.0%
FCF 21.9%
Q4 '25
Gross 57.3%
Operating 29.8%
Net 16.9%
FCF 19.7%
Q1 '26
Gross 56.2%
Operating 28.8%
Net 19.0%
FCF 31.3%
Q2 '26
Gross 55.3%
Operating 29.1%
Net 15.4%
FCF 20.2%
Q3 '26
Gross 55.5%
Operating 29.1%
Net 16.5%
FCF 26.6%
Q4 '26
Gross 51.9%
Operating 26.8%
Net 19.1%
FCF 13.4%
Q1 '27
Gross 51.3%
Operating 19.8%
Net 11.0%
FCF 25.2%
Gross
Operating
Net
FCF
Net income and earnings per share
From fiscal 2017 to 2026, diluted EPS grew 13.0% a year. Loss periods are shown in red.
FY17
Net income $69.4M
FY18
Net income $340M
FY19
Net income −$35.8M
FY20
Net income $142M
FY21
Net income $165M
FY22
Net income $205M
FY23
Net income −$82.3M
FY24
Net income $209M
FY25
Net income $215M
FY26
Net income $190M
Q2 '24
Net income $53.6M
Q3 '24
Net income $53.0M
Q4 '24
Net income $49.5M
Q1 '25
Net income $49.1M
Q2 '25
Net income $54.4M
Q3 '25
Net income $61.0M
Q4 '25
Net income $50.1M
Q1 '26
Net income $47.5M
Q2 '26
Net income $42.2M
Q3 '26
Net income $46.7M
Q4 '26
Net income $53.9M
Q1 '27
Net income $29.2M
FY17
Diluted EPS $1.30
FY18
Diluted EPS $6.34
FY19
Diluted EPS −$0.69
FY20
Diluted EPS $2.78
FY21
Diluted EPS $3.25
FY22
Diluted EPS $4.04
FY23
Diluted EPS −$1.65
FY24
Diluted EPS $4.17
FY25
Diluted EPS $4.29
FY26
Diluted EPS $3.91
Q2 '24
Diluted EPS $1.07
Q3 '24
Diluted EPS $1.06
Q4 '24
Diluted EPS $0.98
Q1 '25
Diluted EPS $0.98
Q2 '25
Diluted EPS $1.09
Q3 '25
Diluted EPS $1.22
Q4 '25
Diluted EPS $1.00
Q1 '26
Diluted EPS $0.95
Q2 '26
Diluted EPS $0.86
Q3 '26
Diluted EPS $0.97
Q4 '26
Diluted EPS $1.13
Q1 '27
Diluted EPS $0.61
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY17
Return on capital 4.5%
Return on equity 8.4%
Return on assets 1.8%
FY18
Return on capital 6.9%
Return on equity 33.9%
Return on assets 8.9%
FY19
Return on capital 1.9%
Return on equity −3.1%
Return on assets −1.0%
FY20
Return on capital 7.7%
Return on equity 12.6%
Return on assets 4.1%
FY21
Return on capital 8.6%
Return on equity 13.0%
Return on assets 4.7%
FY22
Return on capital 8.5%
Return on equity 14.0%
Return on assets 5.8%
FY23
Return on capital −0.6%
Return on equity −5.4%
Return on assets −2.3%
FY24
Return on capital 9.5%
Return on equity 13.5%
Return on assets 6.3%
FY25
Return on capital 9.3%
Return on equity 12.3%
Return on assets 6.4%
FY26
Return on capital 8.1%
Return on equity 10.2%
Return on assets 5.5%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was $246M in fiscal 2026, 22.6% of revenue. Cash from operations minus capital spending.
FY17
Free cash flow $146M
FY18
Free cash flow $198M
FY19
Free cash flow $179M
FY20
Free cash flow $203M
FY21
Free cash flow $213M
FY22
Free cash flow $250M
FY23
Free cash flow $222M
FY24
Free cash flow $239M
FY25
Free cash flow $243M
FY26
Free cash flow $246M
Q2 '24
Free cash flow $59.5M
Q3 '24
Free cash flow $69.5M
Q4 '24
Free cash flow $63.8M
Q1 '25
Free cash flow $53.6M
Q2 '25
Free cash flow $67.8M
Q3 '25
Free cash flow $63.5M
Q4 '25
Free cash flow $58.4M
Q1 '26
Free cash flow $78.2M
Q2 '26
Free cash flow $55.4M
Q3 '26
Free cash flow $75.3M
Q4 '26
Free cash flow $37.6M
Q1 '27
Free cash flow $67.1M
FY17
Cash from operations $149M
Capital spending $3.0M
FY18
Cash from operations $210M
Capital spending $12.5M
FY19
Cash from operations $189M
Capital spending $10.5M
FY20
Cash from operations $217M
Capital spending $14.6M
FY21
Cash from operations $236M
Capital spending $22.2M
FY22
Cash from operations $260M
Capital spending $9.6M
FY23
Cash from operations $230M
Capital spending $7.8M
FY24
Cash from operations $249M
Capital spending $9.6M
FY25
Cash from operations $252M
Capital spending $8.2M
FY26
Cash from operations $258M
Capital spending $11.2M
Cash from operations
Capital spending
Q2 '24
Cash from operations $62.5M
Capital spending $2.9M
Q3 '24
Cash from operations $71.5M
Capital spending $2.0M
Q4 '24
Cash from operations $66.9M
Capital spending $3.1M
Q1 '25
Cash from operations $54.8M
Capital spending $1.2M
Q2 '25
Cash from operations $69.8M
Capital spending $2.0M
Q3 '25
Cash from operations $65.1M
Capital spending $1.6M
Q4 '25
Cash from operations $61.8M
Capital spending $3.5M
Q1 '26
Cash from operations $79.0M
Capital spending $0.8M
Q2 '26
Cash from operations $57.5M
Capital spending $2.1M
Q3 '26
Cash from operations $78.3M
Capital spending $3.0M
Q4 '26
Cash from operations $42.8M
Capital spending $5.2M
Q1 '27
Cash from operations $70.8M
Capital spending $3.7M
Cash from operations
Capital spending
Dividends, buybacks and share count
Prestige Consumer Healthcare Inc. returned $156M to shareholders in fiscal 2026, 63% of free cash flow. The diluted share count fell 2.7%.
FY17
Dividends —
Buybacks $0.0M
FY18
Dividends —
Buybacks $0.0M
FY19
Dividends —
Buybacks $50.0M
FY20
Dividends —
Buybacks $56.7M
FY21
Dividends —
Buybacks $11.9M
FY22
Dividends —
Buybacks $0.0M
FY23
Dividends —
Buybacks $50.0M
FY24
Dividends —
Buybacks $25.0M
FY25
Dividends —
Buybacks $51.5M
FY26
Dividends —
Buybacks $156M
Dividends
Buybacks
Q2 '24
Dividends —
Buybacks $0.0M
Q3 '24
Dividends —
Buybacks $0.0M
Q4 '24
Dividends —
Buybacks $0.0M
Q1 '25
Dividends —
Buybacks $26.0M
Q2 '25
Dividends —
Buybacks $11.8M
Q3 '25
Dividends —
Buybacks $2.4M
Q4 '25
Dividends —
Buybacks $11.3M
Q1 '26
Dividends —
Buybacks $34.8M
Q2 '26
Dividends —
Buybacks $75.0M
Q3 '26
Dividends —
Buybacks $45.8M
Q4 '26
Dividends —
Buybacks $0.7M
Q1 '27
Dividends —
Buybacks $0.0M
Dividends
Buybacks
FY17
Diluted shares 0.05B
FY18
Diluted shares 0.05B
FY19
Diluted shares 0.05B
FY20
Diluted shares 0.05B
FY21
Diluted shares 0.05B
FY22
Diluted shares 0.05B
FY23
Diluted shares 0.05B
FY24
Diluted shares 0.05B
FY25
Diluted shares 0.05B
FY26
Diluted shares 0.05B
Balance sheet
Cash, debt and the ratios that show how comfortably Prestige Consumer Healthcare Inc. can carry it.
FY17
Cash $41.9M
Debt $2.2B
FY18
Cash $32.5M
Debt $2.0B
FY19
Cash $27.5M
Debt $1.8B
FY20
Cash $94.8M
Debt $1.7B
FY21
Cash $32.3M
Debt $1.5B
FY22
Cash $27.2M
Debt $1.5B
FY23
Cash $58.5M
Debt $1.4B
FY24
Cash $46.5M
Debt $1.1B
FY25
Cash $97.9M
Debt $1.0B
FY26
Cash $63.9M
Debt $1.0B
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M |
| Debt incl. finance leases | $1.5B | $1.4B | $1.1B | $1.0B | $1.0B |
| Net debt / EBITDA | 4.0x | 126.5x | 2.9x | 2.5x | 2.8x |
| Debt / equity | 0.9x | 0.9x | 0.7x | 0.5x | 0.5x |
| Interest coverage | 5.1x | −5.1x | 65.9x | 187.1x | — |
| Current ratio | 2.0x | 2.4x | 3.2x | 4.2x | 3.6x |
| Quick ratio | 1.2x | 1.4x | 2.0x | 2.8x | 2.3x |
| Total assets | $3.7B | $3.4B | $3.3B | $3.4B | $3.5B |
| Total liabilities | $2.1B | $1.9B | $1.7B | $1.6B | $1.6B |
| Shareholders' equity | $1.6B | $1.4B | $1.7B | $1.8B | $1.9B |
| Net debt (− = net cash) | $1.5B | $1.3B | $1.1B | $918M | $951M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✓ | ✕ | ✓ | ✓ | ✓ | ✕ | ✓ | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Current ratio rose | — | ✓ | ✕ | ✓ | ✕ | ✕ | ✓ | ✓ | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✓ | ✓ | ✓ | ✕ | ✓ | ✕ | ✓ | ✓ |
| Gross margin rose | — | ✕ | ✓ | ✓ | ✓ | ✕ | ✕ | ✓ | ✓ | ✕ |
| Revenue rose relative to assets | — | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ | ✕ | ✕ |
| F-score | — / 3 | 6 / 9 | 6 / 9 | 8 / 9 | 8 / 9 | 6 / 9 | 6 / 9 | 8 / 9 | 7 / 9 | 5 / 9 |
| Accruals ratio | −2.0% | 3.4% | −6.3% | −2.2% | −2.0% | −1.5% | −8.9% | −1.2% | −1.1% | −2.0% |
| Altman Z'' | 1.25 | 1.82 | 1.62 | 2.27 | 2.51 | 2.74 | 2.30 | 3.57 | 4.04 | 4.04 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $882M | $1.0B | $976M | $963M | $943M | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Net interest income | — | — | — | — | — | −$64.3M | −$69.2M | −$67.2M | −$47.6M | −$42.3M |
| Provision for credit losses | — | — | — | — | — | — | — | $0.0M | $0.0M | $10.3M |
| Gross profit | $500M | $577M | $556M | $552M | $547M | $621M | $625M | $624M | $634M | $596M |
| Operating income | $206M | $215M | $67.5M | $291M | $297M | $330M | −$22.4M | $342M | $337M | $309M |
| Interest expense | $93.5M | $106M | $105M | $96.2M | $82.3M | $64.3M | $4.4M | $5.2M | $1.8M | — |
| Pretax income | $111M | $107M | −$38.1M | $191M | $204M | $262M | −$93.9M | $276M | $284M | $257M |
| Income tax | $41.5M | −$232M | −$2.3M | $48.9M | $39.4M | $57.1M | −$11.6M | $66.7M | $69.6M | $67.2M |
| Net income | $69.4M | $340M | −$35.8M | $142M | $165M | $205M | −$82.3M | $209M | $215M | $190M |
| Diluted EPS | $1.30 | $6.34 | −$0.69 | $2.78 | $3.25 | $4.04 | −$1.65 | $4.17 | $4.29 | $3.91 |
| Diluted shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | $149M | $210M | $189M | $217M | $236M | $260M | $230M | $249M | $252M | $258M |
| Capital expenditure | $3.0M | $12.5M | $10.5M | $14.6M | $22.2M | $9.6M | $7.8M | $9.6M | $8.2M | $11.2M |
| Free cash flow | $146M | $198M | $179M | $203M | $213M | $250M | $222M | $239M | $243M | $246M |
| Depreciation and amortization | $25.8M | $33.4M | $31.8M | $29.0M | $30.2M | $32.1M | $32.6M | $30.7M | $30.2M | $31.3M |
| Stock-based compensation | $8.1M | $8.9M | $7.4M | $7.6M | $8.5M | $9.0M | $12.4M | $14.0M | $11.2M | $10.8M |
| Acquisitions | $0.0M | $0.0M | — | $2.8M | $0.0M | $247M | $0.0M | $10.6M | $8.3M | $124M |
| Share buybacks | $0.0M | $0.0M | $50.0M | $56.7M | $11.9M | $0.0M | $50.0M | $25.0M | $51.5M | $156M |
| Dividends and buybacks | $0.0M | $0.0M | $50.0M | $56.7M | $11.9M | $0.0M | $50.0M | $25.0M | $51.5M | $156M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $41.9M | $32.5M | $27.5M | $94.8M | $32.3M | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M |
| Total debt | $2.2B | $2.0B | $1.8B | $1.7B | $1.5B | $1.5B | $1.3B | $1.1B | $992M | $994M |
| Finance lease liabilities | — | — | — | $5.8M | $9.4M | $7.3M | $4.5M | $1.7M | $23.1M | $20.6M |
| Current assets | $334M | $303M | $301M | $366M | $270M | $293M | $392M | $375M | $448M | $431M |
| Current liabilities | $162M | $123M | $127M | $150M | $122M | $143M | $161M | $117M | $107M | $121M |
| Inventory | $116M | $119M | $120M | $116M | $115M | $120M | $162M | $139M | $148M | $159M |
| Property and equipment, net | $50.6M | $52.6M | $51.2M | $56.0M | $70.1M | $71.3M | $70.4M | $76.5M | $74.5M | $122M |
| Goodwill | $615M | $620M | $579M | $575M | $578M | $579M | $528M | $528M | $527M | $581M |
| Intangible assets | $2.9B | $2.8B | $2.5B | $2.5B | $2.5B | $2.7B | $2.3B | $2.3B | $2.3B | $2.3B |
| Total assets | $3.9B | $3.8B | $3.4B | $3.5B | $3.4B | $3.7B | $3.4B | $3.3B | $3.4B | $3.5B |
| Total liabilities | $3.1B | $2.6B | $2.3B | $2.3B | $2.1B | $2.1B | $1.9B | $1.7B | $1.6B | $1.6B |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $823M | $1.2B | $1.1B | $1.2B | $1.4B | $1.6B | $1.4B | $1.7B | $1.8B | $1.9B |
| Margins | ||||||||||
| Gross margin | 56.7% | 55.4% | 56.9% | 57.3% | 58.0% | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% |
| Operating margin | 23.3% | 20.7% | 6.9% | 30.2% | 31.5% | 30.4% | −2.0% | 30.4% | 29.6% | 28.4% |
| EBITDA margin | 26.2% | 23.9% | 10.2% | 33.2% | 34.7% | 33.3% | 0.9% | 33.2% | 32.3% | 31.3% |
| Net margin | 7.9% | 32.6% | −3.7% | 14.8% | 17.5% | 18.9% | −7.3% | 18.6% | 18.9% | 17.5% |
| FCF margin | 16.5% | 19.0% | 18.3% | 21.0% | 22.6% | 23.0% | 19.7% | 21.3% | 21.4% | 22.6% |
| Net interest share of revenue | — | — | — | — | — | −5.9% | −6.1% | −6.0% | −4.2% | −3.9% |
| Returns | ||||||||||
| Return on capital | 4.5% | 6.9% | 1.9% | 7.7% | 8.6% | 8.5% | −0.6% | 9.5% | 9.3% | 8.1% |
| Return on capital employed | 5.5% | 5.9% | 2.0% | 8.7% | 9.0% | 9.4% | −0.7% | 10.7% | 10.2% | 9.2% |
| Return on equity | 8.4% | 33.9% | −3.1% | 12.6% | 13.0% | 14.0% | −5.4% | 13.5% | 12.3% | 10.2% |
| Return on assets | 1.8% | 8.9% | −1.0% | 4.1% | 4.7% | 5.8% | −2.3% | 6.3% | 6.4% | 5.5% |
| Growth | ||||||||||
| Revenue growth | — | 18.0% | −6.3% | −1.3% | −2.0% | 15.2% | 3.8% | −0.2% | 1.1% | −4.3% |
| Net income growth | — | 389.3% | −110.5% | — | 15.7% | 24.7% | −140.1% | — | 2.5% | −11.3% |
| EPS growth | — | 387.7% | −110.9% | — | 16.9% | 24.3% | −140.8% | — | 2.9% | −8.9% |
| FCF growth | — | 35.6% | −9.5% | 13.3% | 5.3% | 17.3% | −11.3% | 7.9% | 1.6% | 1.3% |
| Share count change | — | 0.3% | −2.7% | −1.8% | −1.0% | 0.5% | −1.9% | 0.6% | −0.2% | −2.7% |
| Financial health | ||||||||||
| Net debt / EBITDA | 9.3x | 7.9x | 17.8x | 5.1x | 4.4x | 4.0x | 126.5x | 2.9x | 2.5x | 2.8x |
| Debt / equity | 2.7x | 1.7x | 1.6x | 1.5x | 1.1x | 0.9x | 0.9x | 0.7x | 0.5x | 0.5x |
| Interest coverage | 2.2x | 2.0x | 0.6x | 3.0x | 3.6x | 5.1x | −5.1x | 65.9x | 187.1x | — |
| Current ratio | 2.1x | 2.5x | 2.4x | 2.4x | 2.2x | 2.0x | 2.4x | 3.2x | 4.2x | 3.6x |
| Quick ratio | 1.4x | 1.5x | 1.4x | 1.7x | 1.3x | 1.2x | 1.4x | 2.0x | 2.8x | 2.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.3% | 1.2% | 1.1% | 1.5% | 2.4% | 0.9% | 0.7% | 0.8% | 0.7% | 1.0% |
| Stock comp / revenue | 0.9% | 0.9% | 0.8% | 0.8% | 0.9% | 0.8% | 1.1% | 1.2% | 1.0% | 1.0% |
| Payouts / FCF | 0.0% | 0.0% | 28.0% | 28.0% | 5.6% | 0.0% | 22.5% | 10.4% | 21.2% | 63.4% |
| Quality scores | ||||||||||
| Piotroski F-score | — | 6.0 | 6.0 | 8.0 | 8.0 | 6.0 | 6.0 | 8.0 | 7.0 | 5.0 |
| Altman Z'' | 1.3 | 1.8 | 1.6 | 2.3 | 2.5 | 2.7 | 2.3 | 3.6 | 4.0 | 4.0 |
| Accruals ratio | −2.0% | 3.4% | −6.3% | −2.2% | −2.0% | −1.5% | −8.9% | −1.2% | −1.1% | −2.0% |
Source: SEC EDGAR XBRL filings (CIK 0001295947). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.